Nootropic Peptides: Semax, Selank and KLOW Blend Research Overview

Nootropic peptide research focuses on compounds proposed to influence neurological function, cognitive performance, stress response, and neuroprotection. Among the most studied compounds in this category are Semax and Selank — both developed originally in Russia and the subject of substantial preclinical and some clinical investigation. This article provides a research-focused overview of both compounds and Bloom Vitality's KLOW Blend, which combines them.

All Bloom Vitality products are supplied strictly for in vitro laboratory and research use only.

Semax

Semax is a synthetic heptapeptide analogue of the adrenocorticotropic hormone (ACTH) fragment ACTH(4–7), with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been used clinically in Russia and Ukraine for neurological indications, though it is not approved as a therapeutic agent in the EU or UK.

Proposed Mechanisms

• BDNF upregulation — Semax has been shown in animal studies to significantly upregulate brain-derived neurotrophic factor (BDNF) and its receptor TrkB, which are central to neuronal survival, synaptic plasticity, and learning
• Dopaminergic and serotonergic system modulation — Research suggests Semax influences dopamine and serotonin receptor expression and signalling
• Neuroprotection — Animal studies have investigated Semax in models of ischaemic stroke, with proposed protective effects on neuronal tissue
• Cognitive enhancement — Preclinical models have shown improved memory consolidation and learning performance

Research Areas

• Cognitive function and memory
• Neuroprotection and neurological recovery models
• Attention and executive function
• Stress and anxiety modulation

Selank

Selank is a synthetic heptapeptide based on the sequence of tuftsin (Thr-Lys-Pro-Arg), with additional amino acids to improve stability: Thr-Lys-Pro-Arg-Pro-Gly-Pro. Like Semax, it was developed in Russia and has been investigated in clinical settings there, though it lacks regulatory approval in Western jurisdictions.

Proposed Mechanisms

• Anxiolytic activity — Selank is proposed to modulate GABAergic and serotonergic signalling, with anxiolytic effects observed in animal models without the sedative properties associated with benzodiazepines
• BDNF modulation — Like Semax, Selank has been associated with increased BDNF expression in preclinical studies
• Immune modulation — Based on its tuftsin-derived structure, Selank has been investigated for effects on cytokine profiles and immune cell activity
• Cognitive effects — Studies suggest Selank may improve memory consolidation and reduce cognitive impairment in stress models

Research Areas

• Anxiety and stress response modulation
• Cognitive function under stress conditions
• Immune regulation
• Neurological function and mood

Semax vs Selank: Key Distinction

Semax is more commonly associated with cognitive enhancement and neuroprotection research, while Selank's primary research profile centres on anxiolytic and stress-modulating effects. Their proposed mechanisms show partial overlap (particularly via BDNF), which has generated research interest in combined protocols.

KLOW Blend

Bloom Vitality's KLOW Blend combines Semax and Selank in a single lyophilised research vial for investigators examining combined nootropic peptide protocols. Individual vials of Semax and Selank are also available separately.

Batch-specific Certificates of Analysis are available on request via our Testing & Quality page.

For research and laboratory use only. This article is provided for informational purposes and does not constitute medical advice.